Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
Launched by VERTEX PHARMACEUTICALS INCORPORATED · Dec 13, 2022
Trial Information
Current as of February 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Diagnosis of diabetes mellitus type 1 or type 2 with
- • Glycosylated hemoglobin A1c (HbA1c) ≤9%; and
- • Presence of bilateral pain in lower extremities due to DPN for at least 1 year
- Key Exclusion Criteria:
- • Painful neuropathy other than DPN
- • History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
- • History of a clinical atherosclerotic event, such as myocardial infarction or stroke, within the past 12 months
- • Other protocol defined Inclusion/Exclusion criteria may apply.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to the innovation and development of transformative therapies for serious diseases, particularly those with significant unmet medical needs. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex specializes in the research and commercialization of treatments for cystic fibrosis and other genetic disorders. Leveraging cutting-edge science and a commitment to patient-centric solutions, Vertex collaborates with healthcare professionals and researchers to advance clinical trials and bring groundbreaking therapies to market, aiming to improve the lives of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winston Salem, North Carolina, United States
Salt Lake City, Utah, United States
Anniston, Alabama, United States
Fleming Island, Florida, United States
Jacksonville, Florida, United States
Tustin, California, United States
Greensboro, North Carolina, United States
Berlin, New Jersey, United States
Hazelwood, Missouri, United States
Baytown, Texas, United States
Monroe, Louisiana, United States
Long Beach, California, United States
Maitland, Florida, United States
Cleveland, Ohio, United States
Fayetteville, North Carolina, United States
Cincinnati, Ohio, United States
Colorado Springs, Colorado, United States
Medford, Oregon, United States
Banning, California, United States
Flossmoor, Illinois, United States
Dearborn, Michigan, United States
Orangeburg, South Carolina, United States
East Greenwich, Rhode Island, United States
Decatur, Georgia, United States
El Dorado, Kansas, United States
Newton, Kansas, United States
North Dartmouth, Massachusetts, United States
Fort Myers, Florida, United States
Saint Peters, Missouri, United States
San Antonio, Texas, United States
Hallandale Beach, Florida, United States
Meridian, Idaho, United States
Wichita, Kansas, United States
Birmingham, Alabama, United States
Largo, Florida, United States
Miami, Florida, United States
Kansas City, Missouri, United States
Saint Louis, Missouri, United States
Charleston, South Carolina, United States
Dallas, Texas, United States
Henderson, Nevada, United States
New York, New York, United States
Bellevue, Washington, United States
Phoenix, Arizona, United States
Evansville, Indiana, United States
Anderson, South Carolina, United States
The Villages, Florida, United States
Waltham, Massachusetts, United States
Orlando, Florida, United States
Boston, Massachusetts, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials